A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Clinical trial NCT01663441 · COMPLETED

Trial details

NCT number: NCT01663441
Sponsor: Beijing Northland Biotech. Co., Ltd.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Chemotherapy-induced Thrombocytopenia

Start date: 2015-03-01
Primary completion: 2017-08-01
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.